NCT05874817View on ClinicalTrials.gov

Retrospective Assessment of AE-Related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

CompletedOBSERVATIONAL
Enrollment

17,517

Participants

Timeline

Start Date

May 1, 2021

Primary Completion Date

May 20, 2022

Study Completion Date

May 20, 2022

Conditions
Melanoma
Trial Locations (1)

07936

Novartis, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT05874817 - Retrospective Assessment of AE-Related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma | Biotech Hunter | Biotech Hunter